NIHR Research Professor and Professor of Experimental Medicine, University of Nottingham, UK
Professor Gisli Jenkins is an NIHR Research Professor and Professor of Experimental Medicine at the University of Nottingham. His research focus is on interstitial lung disease and pulmonary fibrosis in particular. His work focuses on understanding the mechanisms of fibrogenesis to enable the development of stratified approaches to the treatment of progressive pulmonary fibrosis.
He completed his medical training at the University of Southampton before undertaking postgraduate training in Respiratory Medicine in London. During this time he undertook basic scientific training funded by an ARC Fellowship and obtained a PhD in Biochemistry from University College London, before doing post-doctoral studies at the University of California, San Francisco as part of an ARC Clinician Scientist Fellowship.
He is academic lead at the Nottingham Interstitial Lung Diseases Unit and runs the pulmonary fibrosis work strands for the MRC Nottingham Molecular Pathology Node, and the Genomics England Clinical Interpretation Partnership in Respiratory Medicine. His research has been published in leading academic journals including the Journal of Clinical Investigation, Lancet Respiratory Medicine and Science Signalling.
Professor Jenkins’ research group has received funding from Academic organisations including the NIHR, the NC3Rs, the Wellcome Trust, the Medical Research Council, Arthritis Research UK and Asthma UK as well as being awarded industrial contracts in collaboration with Biogen, Galecto, GlaxoSmithKline, MedImmune and Novartis.
Active in the wider research community, he is joint Editor-in-Chief of Thorax and was Chair of the Science and Research Committee until 2018. Professor Jenkins is promotes public patient involvement in biomedical research and is currently a Trustee of the patient charity Action for Pulmonary Fibrosis.Back